Northern Trust
XLO icon

Northern Trust’s Xilio Therapeutics XLO Stock Holding History

Northern Trust’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,758
Closed -$42.6K – 4545
2025
Q4 		$42.6K Hold
4,758
– – ﹤0.01% 4312
2025
Q3 		$56.1K Hold
4,758
– – ﹤0.01% 4265
2025
Q2 		$45.3K Hold
4,758
– – ﹤0.01% 4246
2025
Q1 		$48.3K Buy
4,758
+1,957
+70% +$24.6K ﹤0.01% 4235
2024
Q4 		$37.4K Hold
2,801
– – ﹤0.01% 4301
2024
Q3 		$30.9K Hold
2,801
– – ﹤0.01% 4280
2024
Q2 		$37.1K Buy
2,801
+1,530
+120% +$24K ﹤0.01% 4250
2024
Q1 		$19.2K Hold
1,271
– – ﹤0.01% 4335
2023
Q4 		$9.79K Hold
1,271
– – ﹤0.01% 4420
2023
Q3 		$37.6K Hold
1,271
– – ﹤0.01% 4233
2023
Q2 		$46.6K Buy
1,271
+64
+5% +$2.72K ﹤0.01% 4235
2023
Q1 		$53.6K Buy
1,207
+286
+31% +$12.6K ﹤0.01% 4250
2022
Q4 		$34.7K Hold
921
– – ﹤0.01% 4376
2022
Q3 		$38K Hold
921
– – ﹤0.01% 4399
2022
Q2 		$38K Sell
921
-3,620
-80% -$191K ﹤0.01% 4480
2022
Q1 		$449K Buy
4,541
+39
+0.9% +$6.17K ﹤0.01% 3779
2021
Q4 		$1.01M Buy
+4,502
New +$1.07M ﹤0.01% 3542

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust's XLO Position: Q1 2026 in Review

Northern Trust sold out of Xilio Therapeutics (XLO) in Q1 2026, closing a stake of 4,758 shares — an estimated $42.6K sold.

Northern Trust first reported a position in XLO in Q4 2021 and held it in 17 quarters. The position peaked at $1.01M in Q4 2021. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • Northern Trust reported no remaining Xilio Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Northern Trust sold 4,758 Xilio Therapeutics shares in Q1 2026, an estimated $42.6K.
  • Northern Trust first reported a position in Xilio Therapeutics in Q4 2021 and held it in 17 quarters.
  • Northern Trust's Xilio Therapeutics position peaked at $1.01M in Q4 2021.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.